A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Jakubowiak, A. [1 ]
Offidani, M. [2 ]
Pegourie, B. [3 ]
De La Rubia, J. [4 ]
Garderet, L. [5 ]
Laribi, K. [6 ]
Bosi, A. [7 ]
Marasca, R. [8 ]
Laubach, J. [9 ]
Mohrbacher, A. [10 ]
Carella, A. M. [11 ]
Singhal, A. K. [12 ]
Tsao, L. C. [12 ]
Lynch, M. [13 ]
Bleickardt, E. [13 ]
Jou, Y. M. [13 ]
Palumbo, A. [14 ]
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] Osped Riuniti Ancona, Azienda Osped Univ, Ancona, Italy
[3] Hop Albert Michallon, CHU Grenoble, Grenoble, France
[4] HUP La Fe, Valencia, Spain
[5] Hop St Antoine, F-75571 Paris, France
[6] Ctr Hosp, Le Mans, France
[7] Azienda Osped Univ Careggi, Florence, Italy
[8] Azienda Osped Univ, Policlin Modena, Modena, Italy
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[11] IRCCS San Martino IST, Genoa, Italy
[12] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA
[13] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[14] Osped Molinette, Azienda Osped Univ San Giovanni Battista Torino, Turin, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S103
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [21] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
    Kohmei Kubo
    Mitsuo Hori
    Kensuke Ohta
    Hiroshi Handa
    Kiyohiko Hatake
    Morio Matsumoto
    Shotaro Hagiwara
    Kazuteru Ohashi
    Chiaki Nakaseko
    Kenshi Suzuki
    Shigeki Ito
    Gen Kinoshita
    Suresh G. Shelat
    Masafumi Miyoshi
    Naoki Takezako
    International Journal of Hematology, 2020, 111 : 65 - 74
  • [22] Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan
    Kubo, Kohmei
    Hori, Mitsuo
    Ohta, Kensuke
    Handa, Hiroshi
    Hatake, Kiyohiko
    Matsumoto, Morio
    Hagiwara, Shotaro
    Ohashi, Kazuteru
    Nakaseko, Chiaki
    Suzuki, Kenshi
    Ito, Shigeki
    Kinoshita, Gen
    Shelat, Suresh G.
    Miyoshi, Masafumi
    Takezako, Naoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 65 - 74
  • [23] Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study
    Gross, Zachary
    Rahbari, Ashkon
    Wirtschafter, Eric
    Spektor, Tanya M.
    Udd, Kyle A.
    Bujarski, Sean
    Ghermezi, Michael
    Nosrati, Jason D.
    Vidisheva, Aleksandra
    Eades, Benjamin
    Cecchi, Gary
    Maluso, Tina
    Swift, Regina
    Berenson, James R.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (06) : 621 - 623
  • [24] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Richardson, P.
    Jakubowiak, A.
    Jagannath, S.
    Raab, M.
    Facon, T.
    Vij, R.
    Reece, D.
    White, D.
    Benboubker, L.
    Zonder, J.
    Rossi, J. F.
    Tsao, C.
    Parli, T.
    Kroog, G.
    Singhal, A.
    Lonial, S.
    HAEMATOLOGICA, 2012, 97 : 474 - 474
  • [25] Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.
    Siegel, David
    Jagannath, Sundar
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Graef, Thorsten
    Pietrangelo, Dina
    Lupinacci, Lisa
    Reiser, David
    Rizvi, Syed
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1497 - 1497
  • [26] LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
    Weisel, Katja
    Hungria, Vania
    Quach, Hang
    Yoon, Sung-Soo
    Rodriguez-Otero, Paula
    Sinha, Arijit
    Boyapati, Anita
    Lyon, Charlotte
    Moore, Vygngley
    Inocencio, Tim
    Harnett, James
    Chi, Lei
    Lorenc, Karen Rodriguez
    Kroog, Glenn
    Voorhees, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S63 - S64
  • [27] ELOQUENT-2: Extended safety and efficacy follow-up of the phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M-V
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A.
    Richardson, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 6 - 7
  • [28] Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
    Jakubowiak, A. J.
    Benson, D. M., Jr.
    Bensinger, W.
    Siegel, D. S.
    Zimmerman, T. M.
    Mohrbacher, A.
    Richardson, P. G.
    Afar, D.
    Singhal, A. K.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
    Kumar, Shaji K.
    LaPlant, Betsy R.
    Reeder, Craig B.
    Roy, Vivek
    Halvorson, Alese E.
    Buadi, Francis
    Gertz, Morie A.
    Bergsagel, P. Leif
    Dispenzieri, Angela
    Thompson, Melanie A.
    Crawley, Jamie
    Kapoor, Prashant
    Mikhael, Joseph
    Stewart, Keith
    Hayman, Suzanne R.
    Hwa, Yi L.
    Gonsalves, Wilson
    Witzig, Thomas E.
    Ailawadhi, Sikander
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Rivera, Candido E.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2016, 128 (20) : 2415 - 2422
  • [30] An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.
    Laubach, Jacob
    Nooka, Ajay K.
    Cole, Craig
    O'Donnell, Elizabeth
    Vij, Ravi
    Usmani, Saad Zafar
    Orloff, Gregory Joshua
    Richter, Joshua Ryan
    Redd, Robert
    DiPietro, Heidi
    Cummings, Kristen
    Hansen, Joshua
    Henrick, Patrick M.
    Bassett, Paul
    Schachter, Haley
    Richardson, Paul G.
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345